JSP191 Antibody Conditioning Regimen in MDS/AML Subjects Undergoing Allogenic Hematopoietic Stem Cell Transplantation
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04429191|
Recruitment Status : Recruiting
First Posted : June 12, 2020
Last Update Posted : June 11, 2021
|Condition or disease||Intervention/treatment||Phase|
|MYELODYSPLASTIC SYNDROME; MDS ACUTE MYELOID LEUKEMIA; AML||Biological: Humanized anti-CD117 Monoclonal Antibody (JSP191)||Phase 1|
This is a Phase 1a/b study to evaluate the safety and tolerability of an antibody conditioning regimen known as JSP191, in combination with low dose radiation and fludarabine in subjects with Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) undergoing allogenic blood stem cell transplantation.
Blood Stem Cell transplantation offers the only potentially curative therapy for many forms of Acute Myeloid Leukemia (AML) and for Myelodysplastic Syndrome (MDS). While standard of care conditioning regimens given prior to blood Stem Cell transplantation, such as standard TBI/Flu conditioning are well tolerated, they are associated with increased rates of relapse due to persistence of disease causing Hematopoietic Stem Cells and insufficient graft versus leukemia effect.
The biological conditioning regimen JSP191 is an antibody that binds to CD117. CD117 is the receptor for Stem Cell Factor on blood forming cells. CD117 binding to Stem Cell Factor is critical for survival and maintenance of blood forming stem cells.
The binding of JSP191 to CD117 blocks CD117 from binding to Stem Cell Factor on blood forming stem cells. In the absence of CD117/Stem Cell Factor binding, hematopoietic stem cells that are currently occupying the bone marrow niches in MDS/AML patients are depleted.
This study will investigate the safety and tolerability of adding JSP191 (an anti-CD117 monoclonal antibody therapy) to standard TBI/Flu conditioning regimen in adults with AML and MDS undergoing hematopoietic stem cell transplant.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||40 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Phase 1a/b Study to Evaluate the Safety & Tolerability of JSP191 in Combination With a Regimen of Low Dose Radiation & Fludarabine in Subjects With MDS or AML Undergoing Hematopoietic Cell Transplantation (HCT)|
|Actual Study Start Date :||July 8, 2020|
|Estimated Primary Completion Date :||October 15, 2023|
|Estimated Study Completion Date :||December 8, 2023|
Experimental: Blood Stem Cell Transplant w/ anti-CD117 conditioning
The phase 1a portion of the study plans to assess approximately 3 planned dose cohorts of JSP191: 0.3 mg/kg, 0.6 mg/kg, and 1.0 mg/kg to determine the maximum tolerated dose for expansion. Subjects will receive a single dose of intravenous JSP191 antibody followed by monitoring for antibody clearance. Once the antibody has cleared below a certain level, patients will receive stem cell transplant and be monitored for hematopoietic recovery.
The phase 1b portion of the study will enroll additional subjects at the expansion dose in order to further explore the safety, feasibility, and PK of that dose.
Biological: Humanized anti-CD117 Monoclonal Antibody (JSP191)
Procedure: single intravenous infusion of JSP191 antibody
Other Name: JSP191
- The number of subjects experiencing adverse events and serious adverse events will be assessed. [ Time Frame: Up to 1 year post Donor Cell Transplant (28 days dose limiting toxicity period) ]The number of subjects experiencing adverse events and serious adverse events will be assessed.
- The number of dose limiting toxicities will be assessed. [ Time Frame: Up to 1 year post Donor Cell Transplant (28 days dose limiting toxicity period) ]The number of dose limiting toxicities will be assessed.
- The type of dose limiting toxicities will be assessed. [ Time Frame: Up to 1 year post Donor Cell Transplant (28 days dose limiting toxicity period) ]The type of dose limiting toxicities will be assessed.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04429191
|Contact: Clinical Trials, Jasper Therapeutics, Inc.||650-549-1417||ClinicalTrials@JasperTherapeutics.com|
|United States, California|
|City of Hope Comprehensive Cancer Center||Recruiting|
|Duarte, California, United States, 91010|
|Contact: Nicole Lim, MD, MS firstname.lastname@example.org|
|Stanford, California, United States, 94305|
|Contact: Lori Muffly, MD,MS email@example.com|
|United States, Illinois|
|Rush University Medical Center||Recruiting|
|Chicago, Illinois, United States, 60612|
|Contact: Ankur Varma, MD, MPH firstname.lastname@example.org|
|United States, Oregon|
|Oregon Health & Science University||Recruiting|
|Portland, Oregon, United States, 97239|
|Contact: Clinical Trials Information Line 503-494-1080 email@example.com|
|United States, Utah|
|Huntsman Cancer Institute - University of Utah||Recruiting|
|Salt Lake City, Utah, United States, 84112|
|Contact: Catherine Lee, MD firstname.lastname@example.org|
|United States, Washington|
|Fred Hutchinson Cancer Research Center||Recruiting|
|Seattle, Washington, United States, 98109|
|Contact: Bart Scott, MD email@example.com|
|Principal Investigator:||Lori Muffly, MD,MS||Stanford University|
|Principal Investigator:||Andrew Artz, MD,MS||City of Hope Medical Center|
|Principal Investigator:||Bart Scott, MD||Fred Hutchinson Cancer Research Center|
|Principal Investigator:||Catherine Lee, MD||Huntsman Cancer Institute/ University of Utah|
|Principal Investigator:||Arpita Gandhi, MD||Oregon Health and Science University|
|Principal Investigator:||Ankur Varma, MD,PhD||Rush University Medical Center|